📊 OPRX Key Takeaways
Is OptimizeRx Corp (OPRX) a Good Investment?
OptimizeRx exhibits strong operational efficiency with 67.3% gross margins and robust 17% free cash flow margins, supported by a conservative balance sheet and excellent liquidity. However, flat revenue growth (0% YoY), very low returns on equity (4.0%) and assets (2.9%), and inefficient capital deployment significantly limit upside potential.
OptimizeRx exhibits strong gross margins, solid free cash flow, and a conservative balance sheet, signaling healthy underlying unit economics and disciplined capital structure. However, revenue is flat year over year and returns on capital remain modest, implying the business needs topline reacceleration to translate operating leverage into sustainably higher profitability. Near‑term outlook hinges on maintaining margin gains while reigniting growth.
Why Buy OptimizeRx Corp Stock? OPRX Key Strengths
- Exceptional gross margin of 67.3% with strong free cash flow generation (17% FCF margin)
- Conservative balance sheet with low debt/equity (0.20x) and excellent liquidity (3.04x current ratio)
- Consistent profitability with positive operating cash flow of $18.7M despite minimal capex requirements
- High gross margin (67.3%) indicating an asset-light, scalable model
- Strong liquidity and low leverage (3.04x current ratio; 0.20x D/E; 7.6x interest cover)
- Robust free cash flow (17% FCF margin) supporting reinvestment and resilience
OPRX Stock Risks: OptimizeRx Corp Investment Risks
- Zero revenue growth (0% YoY) indicates complete business stagnation with no organic growth momentum
- Very low capital returns (4% ROE, 2.9% ROA) despite strong margins suggest severe capital inefficiency
- Wide margin compression from 10.7% operating margin to 4.7% net margin signals high overhead or non-operating expenses
- Flat revenue growth (+0.0% YoY) suggests demand or execution headwinds
- Modest profitability at the bottom line (4.7% net margin) and low ROE (4.0%)
- Potential margin pressure if growth investments rise or mix shifts unfavorable
Key Metrics to Watch
- Revenue growth rate and new customer acquisition trends
- Return on equity improvement and capital deployment strategy
- Operating expense ratio and SG&A efficiency
- Revenue growth (YoY)
- Operating margin
OptimizeRx Corp (OPRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.04x current ratio provides a solid financial cushion.
OPRX Profit Margin, ROE & Profitability Analysis
OPRX vs Services Sector: How OptimizeRx Corp Compares
How OptimizeRx Corp compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is OptimizeRx Corp Stock Overvalued? OPRX Valuation Analysis 2026
Based on fundamental analysis, OptimizeRx Corp has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
OptimizeRx Corp Balance Sheet: OPRX Debt, Cash & Liquidity
OPRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: OptimizeRx Corp's revenue has grown significantly by 2,323% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.10 indicates the company is currently unprofitable.
OPRX Revenue Growth, EPS Growth & YoY Performance
OPRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $21.3M | $112.0K | $0.01 |
| Q2 2025 | $18.8M | -$667.0K | $-0.04 |
| Q1 2025 | $19.7M | -$2.2M | $-0.12 |
| Q3 2024 | $16.3M | -$2.9M | $-0.17 |
| Q2 2024 | $13.8M | -$4.0M | $-0.22 |
| Q1 2024 | $13.0M | -$6.4M | $-0.37 |
| Q3 2023 | $15.1M | -$2.9M | $-0.17 |
| Q2 2023 | $13.8M | -$3.8M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
OptimizeRx Corp Dividends, Buybacks & Capital Allocation
OPRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for OptimizeRx Corp (CIK: 0001448431)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OPRX
What is the AI rating for OPRX?
OptimizeRx Corp (OPRX) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OPRX's key strengths?
Claude: Exceptional gross margin of 67.3% with strong free cash flow generation (17% FCF margin). Conservative balance sheet with low debt/equity (0.20x) and excellent liquidity (3.04x current ratio). ChatGPT: High gross margin (67.3%) indicating an asset-light, scalable model. Strong liquidity and low leverage (3.04x current ratio; 0.20x D/E; 7.6x interest cover).
What are the risks of investing in OPRX?
Claude: Zero revenue growth (0% YoY) indicates complete business stagnation with no organic growth momentum. Very low capital returns (4% ROE, 2.9% ROA) despite strong margins suggest severe capital inefficiency. ChatGPT: Flat revenue growth (+0.0% YoY) suggests demand or execution headwinds. Modest profitability at the bottom line (4.7% net margin) and low ROE (4.0%).
What is OPRX's revenue and growth?
OptimizeRx Corp reported revenue of $109.4M.
Does OPRX pay dividends?
OptimizeRx Corp does not currently pay dividends.
Where can I find OPRX SEC filings?
Official SEC filings for OptimizeRx Corp (CIK: 0001448431) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OPRX's EPS?
OptimizeRx Corp has a diluted EPS of $0.27.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OPRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, OptimizeRx Corp has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OPRX stock overvalued or undervalued?
Valuation metrics for OPRX: ROE of 4.0% (sector avg: 16%), net margin of 4.7% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy OPRX stock in 2026?
Our dual AI analysis gives OptimizeRx Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OPRX's free cash flow?
OptimizeRx Corp's operating cash flow is $18.7M, with capital expenditures of $58.0K. FCF margin is 17.0%.
How does OPRX compare to other Services stocks?
Vs Services sector averages: Net margin 4.7% (avg: 10%), ROE 4.0% (avg: 16%), current ratio 3.04 (avg: 1.5).